Nature Medicine
2026-06-23 00:00
DOI:
HASH:606b48daa98904a9738d8088beaeb23f
Shifting the goalposts in obesity drug development
Authors:
Abstract
Obesity drug development must move beyond an emphasis on ever-greater weight loss to prioritize tolerability, sustainable benefits and medication persistence; two recent trials exemplify this shift, with more underway.